Table 1 Assumptions for annual transition probabilities, and ranibizumab dosing regimen
From: Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
| Â | Ranibizumab treatment | No ranibizumab treatment | ||
|---|---|---|---|---|
| Â | Base-case scenario | Sustained-effect scenario | Non-sustained-effect scenario | Â |
Annual transition probabilities* | Â | Â | Â | Â |
Time horizon | Â | Â | Â | Â |
   Years 1 and 2 | Results of MARINA, 0.5 mg ranibizumab arm. | As for base-case | As for base-case | Results of MARINA, sham arm. |
   Years 3 and 4 | Year 2 MARINA data, 0.5 mg ranibizumab arm. | As for base-case | Year 2 MARINA data, sham arm | Year 2 MARINA data, sham arm. |
   Years 5 to 10 | Year 5 to 10 progression rates of the geographic atrophy form of age-related macular degeneration | No further transitions (neither increasing nor decreasing visual acuity) | Year 2 MARINA data, sham arm, progression rates decreasing by 40% each year | Year 2 MARINA data, sham arm, progression rates decreasing by 40% each year |
Ranibizumab dosing regimen | Â | Â | Â | Â |
| Â | One dose monthly for the first 2 years, then every 3 months until end of Year 4. No ranibizumab thereafter. | Three doses at monthly intervals, then every 3 months until the end of Year 2. No ranibizumab thereafter. | One dose monthly for the first 2 years. No ranibizumab thereafter. | - |